National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov

Clinical Trials by Cancer Site

Brain and Central Nervous System Cancers

Brain and central nervous system (CNS) cancers affect both children and adults. Among children, CNS tumors are the second most commonly diagnosed type of cancer. It is a condition that is most commonly diagnosed in Caucasians and, in particular, Caucasian males. The causes of primary brain and central nervous system tumors are not known.

Treatment options for brain and CNS tumors may vary depending on the patient's age, size and location of the tumor, stage of disease, and other medical conditions, and should be discussed with the patient's physician.

Brain Cancer Clinical Trials

The Center for Cancer Research (CCR), NCI's largest division doing research on campus, conducts brain tumor clinical trials at the NIH Clinical Center in Bethesda, Md. NCI accepts referrals to brain tumor clinical trials conducted in Bethesda, Md., through its Clinical Trials Referral Office (formerly called the Clinical Studies Support Center) at 1-888-NCI-1937 (1-888-624-1937).

NCI is currently conducting the following trials for patients with brain and central nervous system cancers. Click on the trials below for additional details, including a summary of eligibility criteria, treatment plan, and information on how to contact the principal investigators and their staff directly.


  
Trial and Protocol Number
Brain Tumor
No Phase
Comparative Trial of Pediatric CNS Tumor Activity as Assessed by PET Imaging and Proton Magnetic Resonance Spectroscopy Imaging (MRSI)
NCI-03-C-0278

Principal Investigator:Referral Contact:
Katherine E. WarrenRobyn Bent
301-496-4256301-496-8009
rbent@mail.nih.gov
A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative
NCI-02-C-0140

Principal Investigator:Referral Contact:
Howard A. FineCharisse Garcia
301-402-6298301-402-6298
garciacr@mail.nih.gov
Evaluation of the Natural History of Patients With Tumors of the Central Nervous System
NCI-01-C-0070

Principal Investigator:Referral Contact:
Howard A. FineCharisse Garcia
301-402-6298301-402-6298
garciacr@mail.nih.gov


  
Trial and Protocol Number
Brain Tumor (Adult)
Phase II
A Phase II Trial of Sunitinib in the Treatment of Recurrrent Malignant Gliomas
NCI-08-C-0168

Principal Investigator:Referral Contact:
Teri KreislCharisse Garcia
301-402-3423301-402-6298
garciacr@mail.nih.gov
A Phase II Trial of Tandutinib in Combination With Bevacizumab for Patients With Recurrent High-Grade Gliomas
NCI-08-C-0101

Principal Investigator:Referral Contact:
Howard A. FineCharisse Garcia
301-402-6298301-402-6298
garciacr@mail.nih.gov
A Phase II Trial of Enzastaurin (LY317615) in Combination With Bevacizumab in Adults With Recurrent Malignant Gliomas
NCI-08-C-0015

Principal Investigator:Referral Contact:
Howard A. FineCharisse Garcia
301-402-6298301-402-6298
garciacr@mail.nih.gov
A Phase II Trial of Bevacizumab and Irinotecan for Patients With Recurrent High-Grade Gliomas Immediately Following Tumor Progression After Treatment With Bevacizumab Alone: A Companion Trial to NCI Study 06-C-0064
NCI-06-C-0250

Principal Investigator:Referral Contact:
Howard A. FineCharisse Garcia
301-402-6298301-402-6298
garciacr@mail.nih.gov
A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination With Temodar and Radiation Therapy in Patients With High Grade Gliomas
NCI-06-C-0112

Principal Investigator:Referral Contact:
Kevin CamphausenSharon L. Smith
301-496-5457301-496-5457
smiths@mail.nih.gov
Phase II Trial of Bevacizumab for Patients With Recurrent High-Grade Glioma
NCI-06-C-0064

Principal Investigator:Referral Contact:
Howard A. FineCharisse Garcia
301-402-6298301-402-6298
garciacr@mail.nih.gov
A Phase II Trial of Tamoxifen and Bortezomib in Patients With Recurrent High-Grade Gliomas
NCI-05-C-0137

Principal Investigator:Referral Contact:
Howard A. FineCharisse Garcia
301-402-6298301-402-6298
garciacr@mail.nih.gov
Phase I/II
Phase I/II Study of ZD6474 in Patients With Recurrent High-Grade or Progressive Low-Grade Gliomas
NCI-06-C-0063

Principal Investigator:Referral Contact:
Howard A. FineCharisse Garcia
301-402-6298301-402-6298
garciacr@mail.nih.gov
Phase I
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
NCI-07-C-0053

Principal Investigator:Referral Contact:
Howard A. FineCharisse Garcia
301-402-6298301-402-6298
garciacr@mail.nih.gov
No Phase
Urinary and Serum VEGF and MMP Levels for Radiation Therapy in Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence
NCI-04-C-0200

Principal Investigator:Referral Contact:
Kevin CamphausenSharon L. Smith
301-496-5457301-496-5457
smiths@mail.nih.gov


  
Trial and Protocol Number
Brain Tumor (Childhood)
Phase II
Phase II Study of Pegylated Interferon Alfa-2b (PEG-Intron) in Children With Diffuse Pontine Gliomas
NCI-02-C-0193

Principal Investigator:Referral Contact:
Katherine E. WarrenRobyn Bent
301-496-4256301-496-8009
rbent@mail.nih.gov
No Phase
An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
NCI-06-C-0219

Principal Investigator:Referral Contact:
Katherine E. WarrenRobyn Bent
301-496-4256301-496-8009
rbent@mail.nih.gov


  
Trial and Protocol Number
AIDS Related Cancers
Phase II
AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy
NCI-06-C-0051

Principal Investigator:Referral Contact:
Robert YarchoanKaren Aleman
301-496-8959301-496-8959
1-800-243-2732 ext. 4 (Toll Free)
alemank@mail.nih.gov


  
Trial and Protocol Number
Solid Tumor (Childhood)
Phase I
Multiple Ascending Dose (MAD) Phase I Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Children and Adolescents With Advanced Solid Tumors
NCI-08-C-0010

Principal Investigator:Referral Contact:
Frank BalisPediatric Oncology
301-496-00851-877-624-4878
(Toll free)

A Phase I Trial and Pharmacokinetic Study of Trabectedin (YONDELIS®, ET-743) in Children and Adolescents With Relapsed or Refractory Solid Tumors
NCI-07-C-0054

Principal Investigator:Referral Contact:
Elizabeth FoxPediatric Oncology
301-402-66411-877-624-4878
(Toll free)



Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov National Cancer Institute Clinical Trials at NIH - Be part of the cure